The company has tapped Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho to serve as joint book-running managers for the transaction. This offering utilizes a shelf registration statement previously filed with the Securities and Exchange Commission in November 2025 and declared effective the following month. REGENXBIO expects to file a preliminary prospectus supplement detailing the specific terms of the deal with federal regulators shortly.
In section Releases
REGENXBIO Seeks $100 Million in Common Stock Offering
Rockville-based biotechnology firm REGENXBIO announced plans to raise $100 million through an underwritten public offering of its common stock. The move, contingent on prevailing market conditions, includes an option for underwriters to acquire an additional 15% of shares within 30 days to cover potential over-allotments of the equity.
REGENXBIO continues to focus on its gene therapy pipeline, which features late-stage candidates like RGX-202 for Duchenne muscular dystrophy and the ABBV-RGX-314 program for retinal diseases. While the company pursues this capital injection to support its ongoing operations, the final size and execution of the offering remain subject to market fluctuations and regulatory oversight.
Comments (0)
No comments yet. Be the first!